2021 CSCO临床指南:鼻咽癌的诊断和治疗(英文版)

2021-10-26 中国临床肿瘤学会 Cancer Commun (Lond)

鼻咽癌是具有“中国特色”的癌症,主要发病区域集中在我国华南、华东、华西地区。

中文标题:

2021 CSCO临床指南:鼻咽癌的诊断和治疗(英文版)

英文标题:

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma

发布机构:

中国临床肿瘤学会

发布日期:

2021-10-26

简要介绍:

鼻咽癌是具有“中国特色”的癌症,主要发病区域集中在我国华南、华东、华西地区。2021年CSCO鼻咽癌诊疗指南中复发转移性鼻咽癌综合治疗的更新主要包括三个方面:

一、新增“顺铂+5-FU(PF)+局部放疗”为一线治疗Ⅰ级推荐(1A类证据),新增“吉西他滨+顺铂(GP)+恩度”为一线治疗Ⅲ级推荐(2B类证据);

二、新增“特瑞普利单抗”为二线及以上治疗Ⅲ级推荐(2B类证据);

三、指南新增“特瑞普利单抗”为三线及以上治疗Ⅰ级推荐(2A类证据),同时新增“卡瑞利珠单抗” 为三线及以上治疗Ⅰ级推荐(2A类证据)。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南:鼻咽癌的诊断和治疗(英文版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=61a591c002239a89, title=2021 CSCO临床指南:鼻咽癌的诊断和治疗(英文版), enTitle=The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma, guiderFrom=Cancer Commun (Lond), authorId=0, author=, summary=鼻咽癌是具有“中国特色”的癌症,主要发病区域集中在我国华南、华东、华西地区。, cover=https://img.medsci.cn/20211027/1635323328728_5579292.jpg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Oct 26 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p style="color: #373737;">鼻咽癌是具有&ldquo;中国特色&rdquo;的癌症,主要发病区域集中在我国华南、华东、华西地区。2021年CSCO鼻咽癌诊疗指南中复发转移性鼻咽癌综合治疗的更新主要包括三个方面:</p> <p style="color: #373737;">一、新增&ldquo;顺铂+5-FU(PF)+局部放疗&rdquo;为一线治疗Ⅰ级推荐(1A类证据),新增&ldquo;吉西他滨+顺铂(GP)+恩度&rdquo;为一线治疗Ⅲ级推荐(2B类证据);</p> <p style="color: #373737;">二、新增&ldquo;特瑞普利单抗&rdquo;为二线及以上治疗Ⅲ级推荐(2B类证据);</p> <p style="color: #373737;">三、指南新增&ldquo;特瑞普利单抗&rdquo;为三线及以上治疗Ⅰ级推荐(2A类证据),同时新增&ldquo;卡瑞利珠单抗&rdquo; 为三线及以上治疗Ⅰ级推荐(2A类证据)。</p>, tagList=[TagDto(tagId=1574, tagName=鼻咽癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1574, guiderKeyword=鼻咽癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7134, appHits=215, showAppHits=0, pcHits=2471, showPcHits=6918, likes=2, shares=16, comments=5, approvalStatus=1, publishedTime=Wed Oct 27 17:13:05 CST 2021, publishedTimeString=2021-10-26, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Oct 27 16:33:00 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 11:04:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CSCO临床指南:鼻咽癌的诊断和治疗(英文版).pdf)])
2021 CSCO临床指南:鼻咽癌的诊断和治疗(英文版).pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2106149, encodeId=f0e5210614985, content=求分享 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf2f8291735, createdName=ms4000000859379629, createdTime=Thu Dec 15 10:07:31 CST 2022, time=2022-12-15, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204920, encodeId=b598120492086, content=好,及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a795381180, createdName=ms2000001275607784, createdTime=Tue Mar 22 12:39:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182758, encodeId=52bf1182e58a5, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069408, encodeId=dff010694088a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210324/33c1f9363bed4ad296d0b22c77b78822/bf54abd76db441b7a1ca37f101219419.jpg, createdBy=f9135472594, createdName=Dr lv, createdTime=Thu Nov 11 23:16:03 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064632, encodeId=bd581064632c2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:31:25 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2022-12-15 ms4000000859379629 来自山西省

    求分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2106149, encodeId=f0e5210614985, content=求分享 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf2f8291735, createdName=ms4000000859379629, createdTime=Thu Dec 15 10:07:31 CST 2022, time=2022-12-15, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204920, encodeId=b598120492086, content=好,及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a795381180, createdName=ms2000001275607784, createdTime=Tue Mar 22 12:39:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182758, encodeId=52bf1182e58a5, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069408, encodeId=dff010694088a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210324/33c1f9363bed4ad296d0b22c77b78822/bf54abd76db441b7a1ca37f101219419.jpg, createdBy=f9135472594, createdName=Dr lv, createdTime=Thu Nov 11 23:16:03 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064632, encodeId=bd581064632c2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:31:25 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2022-03-22 ms2000001275607784

    好,及时

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2106149, encodeId=f0e5210614985, content=求分享 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf2f8291735, createdName=ms4000000859379629, createdTime=Thu Dec 15 10:07:31 CST 2022, time=2022-12-15, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204920, encodeId=b598120492086, content=好,及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a795381180, createdName=ms2000001275607784, createdTime=Tue Mar 22 12:39:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182758, encodeId=52bf1182e58a5, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069408, encodeId=dff010694088a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210324/33c1f9363bed4ad296d0b22c77b78822/bf54abd76db441b7a1ca37f101219419.jpg, createdBy=f9135472594, createdName=Dr lv, createdTime=Thu Nov 11 23:16:03 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064632, encodeId=bd581064632c2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:31:25 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2022-01-10 新心相映

    很及时

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2106149, encodeId=f0e5210614985, content=求分享 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf2f8291735, createdName=ms4000000859379629, createdTime=Thu Dec 15 10:07:31 CST 2022, time=2022-12-15, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204920, encodeId=b598120492086, content=好,及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a795381180, createdName=ms2000001275607784, createdTime=Tue Mar 22 12:39:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182758, encodeId=52bf1182e58a5, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069408, encodeId=dff010694088a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210324/33c1f9363bed4ad296d0b22c77b78822/bf54abd76db441b7a1ca37f101219419.jpg, createdBy=f9135472594, createdName=Dr lv, createdTime=Thu Nov 11 23:16:03 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064632, encodeId=bd581064632c2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:31:25 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-11-11 Dr lv

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2106149, encodeId=f0e5210614985, content=求分享 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bf2f8291735, createdName=ms4000000859379629, createdTime=Thu Dec 15 10:07:31 CST 2022, time=2022-12-15, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=1204920, encodeId=b598120492086, content=好,及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a795381180, createdName=ms2000001275607784, createdTime=Tue Mar 22 12:39:37 CST 2022, time=2022-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182758, encodeId=52bf1182e58a5, content=很及时, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33632003406, createdName=新心相映, createdTime=Mon Jan 10 10:03:11 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069408, encodeId=dff010694088a, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210324/33c1f9363bed4ad296d0b22c77b78822/bf54abd76db441b7a1ca37f101219419.jpg, createdBy=f9135472594, createdName=Dr lv, createdTime=Thu Nov 11 23:16:03 CST 2021, time=2021-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1064632, encodeId=bd581064632c2, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Thu Oct 28 10:31:25 CST 2021, time=2021-10-28, status=1, ipAttribution=)]
    2021-10-28 1207866fm50(暂无昵称)

    谢谢分享

    0

拓展阅读

2010 鼻咽癌调强放疗靶区及剂量设计指引专家共识

中国鼻咽癌临床分期工作委员会 · 2011-07-01

2012 ESMO临床实践指南:鼻咽癌的诊断、治疗与随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2016 ACR适宜性标准:鼻咽癌

美国放射学会(ACR,American College of Radiology) · 2016-04-30

2016 英国国家多学科指南:鼻咽癌

国外肿瘤科相关专家小组(统称) · 2016-05-30

中国鼻咽癌分期2017版(2008鼻咽癌分期修订专家共识)

中国鼻咽癌临床分期工作委员会 · 2017-10-30

2017 国际指南:鼻咽癌临床靶区勾画

国外肿瘤科相关专家小组(统称) · 2017-11-15